Gildeuretinol slows retinal lesion growth in Stargardt disease trial

The TEASE-1 randomized, placebo-controlled trial evaluated oral gildeuretinol acetate in 50 randomized participants with Stargardt disease, incorporating additional natural history cases, over 24 months. The trial reported that the growth rate of retinal atrophic lesions was slower with gildeuretinol (0.182 mm/y) than in the untreated group (0.232 mm/y), a 21.6% relative reduction, with a similar but smaller effect in a sensitivity analysis restricted to randomized participants; adverse events were mostly mild or moderate and similar between groups, with no treatment-related serious AEs. The authors state that further research is needed to determine the clinical relevance of this end point, and note there is currently no approved treatment for Stargardt disease.

Most relevant for: Patients with Stargardt disease, the most common macular dystrophy, who currently have no approved treatment option.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.